A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

@article{Hilgers2005API,
  title={A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors},
  author={Werner Hilgers and Sandrine Faivre and St{\'e}phanie Chieze and J{\'e}r{\^o}me Alexandre and François Lokiec and François Goldwasser and Eric Raymond and Carmen Kahatt and Abdelkrim Taamma and Garry Weems and John R. MacDonald and Jean-Louis Misset and Esteban Cvitkovic},
  journal={Investigational New Drugs},
  year={2005},
  volume={24},
  pages={311-319}
}
  • Werner Hilgers, Sandrine Faivre, +10 authors Esteban Cvitkovic
  • Published in Investigational New Drugs 2005
  • DOI:10.1007/s10637-005-5055-6
SummaryBackground: To determine maximum tolerated dose (MTD), recommended dose, safety and pharmacokinetics of irofulven combined with cisplatin in advanced solid tumor patients. Patients and methods: Cisplatin and irofulven were given sequentially i.v. over 30 min on day 1 and 15 every 4 weeks. Four dose levels (DL) were explored: irofulven (mg/kg)/cisplatin (mg/m2): DL1: 0.3/30; DL2: 0.4/30; DL3: 0.4/40; DL4: 0.5/40. Dose-limiting toxicity (DLT) included dosing omission and delay >1 week. MTD… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

Jérôme Alexandre, Carmen Kahatt, +10 authors Esteban Cvitkovic
  • Investigational New Drugs
  • 2007
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry

Dilani D. De Silva, Sylvie Rapior, +4 authors Kevin D. Hyde
  • Fungal Diversity
  • 2013
VIEW 2 EXCERPTS
CITES BACKGROUND

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model

Michael J. Kelner, Trevor C. McMorris, Rafael J. Rojas, Leita A. Estes, Pharnuk Suthipinijtham
  • Cancer Chemotherapy and Pharmacology
  • 2008
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients

J Alexandre, E Raymond, M Ould-Kaci
  • Clin Cancer Res
  • 2004
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 3 EXCERPTS

A phase I combination trial of irofulven and gemcitabine in patients with advanced solid malignancies

S Witta, G Eckhardt, M Rothenberg
  • Proc Am Soc Clin Oncol
  • 2003

Phase I and pharmacokinetic (PK) study of irofulven (IROF) and capecitabine (CAP) in combination using an intermittent schedule in advanced solid tumors

J Alexandre, F Bertheault-Cvitkovic, +3 authors P Herait
  • Proc Am Soc Clin Oncol 22:154,
  • 2003